ArticleDiagnostics (Basel, Switzerland)2020
Biomarker Utility for Peripheral Artery Disease Diagnosis in Real Clinical Practice: A Prospective Study.
Article in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 37 citations in OpenAlex.
- Article
- Prediction of Major Adverse Limb Events in Females with Peripheral Artery Disease using Blood-Based Biomarkers and Clinical Features.Journal of cardiovascular translational research · 2025Article
- An evaluation of inflammatory and endothelial dysfunction markers as determinants of peripheral arterial disease in those with diabetes mellitus.Scientific reports · 2024Article
- Inflammatory Biomarkers to Predict Major Adverse Cardiovascular Events in Patients with Carotid Artery Stenosis.Medicina (Kaunas, Lithuania) · 2024Article
- A machine learning algorithm for peripheral artery disease prognosis using biomarker data.iScience · 2024Article
- Prediction of Peripheral Artery Disease Prognosis Using Clinical and Inflammatory Biomarker Data.Journal of inflammation research · 2024Article
- Assessment of Inflammatory Hematological Ratios (NLR, PLR, MLR, LMR and Monocyte/HDL-Cholesterol Ratio) in Acute Myocardial Infarction and Particularities in Young Patients.International journal of molecular sciences · 2023Review
- Endothelial Dysfunction in Primary Sjögren's Syndrome: Correlation with Serum Biomarkers of Disease Activity.International journal of molecular sciences · 2023Article
- Increasing Awareness for Peripheral Artery Disease through the Identification of Novel Biomarkers.Biomolecules · 2023Article
- Analysis of the Comorbid Course of Chronic Obstructive Pulmonary Disease.Journal of personalized medicine · 2023Article
- The Significance of Low Magnesium Levels in COVID-19 Patients.Medicina (Kaunas, Lithuania) · 2023Review
- Validating fatty acid binding protein 3 as a diagnostic and prognostic biomarker for peripheral arterial disease: A three-year prospective follow-up study.EClinicalMedicine · 2023Article
- Relationship between serum homocysteine, fibrinogen, lipoprotein-a level, and peripheral arterial disease: a dose-response meta-analysis.European journal of medical research · 2022Review
- The Genetic Architecture of the Etiology of Lower Extremity Peripheral Artery Disease: Current Knowledge and Future Challenges in the Era of Genomic Medicine.International journal of molecular sciences · 2022Review
- Diet Quality and Health in Older Americans.Nutrients · 2022Article
- Asprosin induces vascular endothelial-to-mesenchymal transition in diabetic lower extremity peripheral artery disease.Cardiovascular diabetology · 2022Article
- Circulating Biomarkers in Lower Extremity Artery Disease.European cardiology · 2022Review
- Fibrinogen and Atherosclerotic Cardiovascular Diseases-Review of the Literature and Clinical Studies.International journal of molecular sciences · 2021Review
- The Implication of Reactive Oxygen Species and Antioxidants in Knee Osteoarthritis.Antioxidants (Basel, Switzerland) · 2021Review
- Vascular Biomarkers: Physics Parameters and Circulating Molecules Can Be Two Faces of the Same Coin.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peripheral arterial disease (PAD) is a common manifestation of generalized atherosclerosis, which affects more than 200 million patients worldwide. Currently, there is no ideal biomarker for PAD risk stratification and diagnosis. The goal of this research was to investigate the levels of inflammation biomarkers and cystatin C and to explore their utility for the diagnosis of PAD. The study included 296 participants, distributed in two groups: 216 patients diagnosed with PAD and 80 patients without PAD as controls. All studied biomarker levels (C-reactive protein, CRP; fibrinogen; erythrocyte sedimentation rate, ESR; neopterin; beta 2-microglobulin, B2-MG; and cystatin C) were significantly higher in the PAD group and indirectly correlated with the ankle-brachial index (ABI). The final logistic regression model included an association of neopterin, fibrinogen, and cystatin C as the most efficient markers for the prediction of PAD diagnosis. When comparing the area under the curve (AUC) for all biomarkers, the value for neopterin was significantly higher than those of all the other analyzed biomarkers. In agreement with previous studies, this research shows that markers such as fibrinogen, CRP, ESR, B2-MG, and cystatin C have significant value for the diagnosis of PAD, and also clearly underlines the accuracy of neopterin as a leading biomarker in PAD prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.